Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Enliven Therapeutics, Inc.ELVN · Entity 4024 | Director | February 17, 2026 | February 19, 2026 |
| Gritstone bio, Inc.GRTS · Entity 80946 | Director | June 17, 2022 | June 22, 2022 |
| KINETA, INC./DEYMTX · Entity 77778 | Director | June 02, 2021 | June 04, 2021 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | May 18, 2022 | September 06, 2022 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director | October 01, 2026 | October 02, 2026 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director | June 05, 2025 | June 09, 2025 |
| Tango Therapeutics, Inc.BCTG · Entity 1497 | Director | September 02, 2020 | September 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Enliven Therapeutics, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 22,647 |
Reported balance
After 2026-02-17 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2026-02-17 · Sale · Disposed 1,230 · Balance 22,647 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust"). F2: This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: The shares are held of record by the Heyman Daigle Trust. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 25,545 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 25,545 F4: The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member. |
| Common StockSEC Table I · non-derivative | Direct | 123,673 |
Reported balance
Holding disclosure · report date 2026-02-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 123,673 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust").
F2: This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: The shares are held of record by the Heyman Daigle Trust.
F4: The shares are held of record by RAHD Capital LLC, for which the Reporting Person serves as a managing member.
Gritstone bio, Inc.
Report date June 17, 2022 · Filed June 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.22 · Expires 2032-06-16 | Direct | 19,000 |
Reported balance
After 2022-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-17 · Grant · Acquired 19,000 · Balance 19,000 F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest and become exercisable on the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through the applicable vesting date.
KINETA, INC./DE
Report date June 02, 2021 · Filed June 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.26 · Expires 2031-06-01 | Direct | 14,800 |
Reported balance
After 2021-06-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-02 · Grant · Acquired 14,800 · Balance 14,800 F1: The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021.
Metacrine, Inc.
Report date May 18, 2022 · Filed September 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2032-05-17 | Direct | 16,500 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 16,500 · Balance 16,500 F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day immediately prior to the date of the Issuer's 2023 annual meeting of stockholders.
Oric Pharmaceuticals, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,300 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 3,500 · Balance 41,800 Row 2 · 2026-10-01 · Sale · Disposed 3,500 · Balance 38,300 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 203,472 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Sale · Disposed 3,200 · Balance 203,472 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2028-02-28 | Direct | 26,700 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 3,500 · Balance 26,700 F4: The shares subject to the option are fully vested and immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
F2: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
F4: The shares subject to the option are fully vested and immediately exercisable.
PMV Pharmaceuticals, Inc.
Report date June 05, 2025 · Filed June 09, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2035-06-05 | Direct | 33,500 |
Reported balance
After 2025-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-05 · Grant · Acquired 33,500 · Balance 33,500 F1: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders.
Tango Therapeutics, Inc.
Report date September 02, 2020 · Filed September 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,600 |
Reported balance
Holding disclosure · report date 2020-09-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 40,600 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RayzeBio, Inc.
Report date February 26, 2024 · Filed February 27, 2024
Section 16 reporting ended · disclosed 2024-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-26 transaction · row 1
1 source rowRow 1 · 2024-02-26 · Disposition to issuer · Disposed 367,446 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · derivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 3,500 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 3,200 | $12.91 | $41,325.12 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 203,472 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 3,500 | $12.91 | $45,199.35 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,300 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 21:50 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 3,500 | $1.60 | $5,600.00 |
DisclosureSEC source: 0001584759-26-000017 · form4-10022026_091044.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 3,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · derivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,200 Underlying: Common Stock · 3,500 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 6,100 | $12.02 | $73,322.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 206,672 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 7,000 | $12.02 | $84,140.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,300 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:15 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 3,500 | $1.60 | $5,600.00 |
DisclosureSEC source: 0001584759-26-000015 · form4-07282026_080709.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2026 Filed Jul 8, 2026 20:35 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 300 | $12.00 | $3,600.00 |
DisclosureSEC source: 0001584759-26-000012 · form4-07082026_080727.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 212,772 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 23:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,230 | $26.18 | $32,196.36 |
DisclosureSEC source: 0001584759-26-000009 · form4-02192026_110223.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 22,647 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $25.765 to $26.6949. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by the Heyman Daigle Trust. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 01:00 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 19,234 | $0.00 Strike: $27.16 | $0.00 |
DisclosureSEC source: 0001584759-26-000008 · form4-02182026_010204.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,234 Underlying: Common Stock · 19,234 shares Expires 2036-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of the Issuer's stockholders or (ii) the date of the 2027 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director through the applicable vesting date. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:33 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 718 | $26.96 | $19,354.41 |
DisclosureSEC source: 0001584759-26-000007 · form4-01222026_100111.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 23,877 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $26.725 to $27.3454. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by the Heyman Daigle Trust. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 22:33 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 512 | $26.46 | $13,547.11 |
DisclosureSEC source: 0001584759-26-000007 · form4-01222026_100111.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 24,595 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust"). F2 · price: This transaction was executed in multiple trades at prices ranging from $25.7133 to $26.7111. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by the Heyman Daigle Trust. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 00:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 3,200 | $12.00 | $38,414.72 |
DisclosureSEC source: 0001584759-26-000006 · form4-01212026_120124.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 213,072 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 00:19 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | SaleCommon Stock | 3,500 | $12.00 | $42,016.10 |
DisclosureSEC source: 0001584759-26-000006 · form4-01212026_120124.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,800 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC. F2 · price: Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 09, 2026 Filed Jan 12, 2026 22:11 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 4,285 | $25.00 | $107,125.43 |
DisclosureSEC source: 0001584759-26-000004 · form4-01122026_100112.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 25,107 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust"). F6 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5 · ownership.nature: The shares are held of record by the Heyman Daigle Trust. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:11 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 8,015 | $25.04 | $200,655.53 |
DisclosureSEC source: 0001584759-26-000004 · form4-01122026_100112.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 29,392 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by the Reporting Person and by Richard A. Heyman and Anne E. Daigle Trust, UAD 01/01/1995, as amended November 1, 2016, for which the Reporting Person serves as trustee (the "Heyman Daigle Trust"). F4 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F5 · ownership.nature: The shares are held of record by the Heyman Daigle Trust. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:11 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,620 | $25.00 | $40,500.00 |
DisclosureSEC source: 0001584759-26-000004 · form4-01122026_100112.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 25,545 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024 by RAHD Capital LLC, for which the Reporting Person serves as a managing member. F2 · ownership.nature: The shares are held of record by RAHD Capital LLC. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:46 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $8.17 | $0.00 |
DisclosureSEC source: 0001584759-26-000003 · form4-01062026_090104.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 1,447 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001584759-25-000004 · form4-10032025_111055.xml · derivative · entry 6 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,253 Underlying: Common Stock · 1,447 shares Expires 2032-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 18,125 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001584759-25-000004 · form4-10032025_111055.xml · derivative · entry 5 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,125 shares Expires 2028-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionStock Option (right to buy) · Derivative | 13,228 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001584759-25-000004 · form4-10032025_111055.xml · derivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,700 Underlying: Common Stock · 13,228 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and immediately exercisable. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 1,447 | $3.75 | $5,426.25 |
DisclosureSEC source: 0001584759-25-000004 · form4-10032025_111055.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 23:18 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | Exercise / conversionCommon Stock | 31,353 | $1.60 | $50,164.80 |
DisclosureSEC source: 0001584759-25-000004 · form4-10032025_111055.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:26 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 33,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-25-016266 · form4-06092025_080655.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 22:38 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 23,014 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001415889-25-003520 · form4-02102025_100215.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,014 Underlying: Common Stock · 23,014 shares Expires 2035-02-06 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2025 annual meeting of the Issuer's stockholders or (ii) the date of the 2026 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:44 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001415889-25-000785 · form4-01062025_090141.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 753 | $30.00 | $22,591.58 |
DisclosureSEC source: 0001415889-24-025500 · form4-10222024_081053.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 27,165 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F3 · ownership.nature: The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 20:18 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 817 | $30.00 | $24,512.45 |
DisclosureSEC source: 0001415889-24-025500 · form4-10222024_081053.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,673 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 15, 2024 Filed Oct 17, 2024 21:06 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $27.67 | $35,143.31 |
DisclosureSEC source: 0001415889-24-025381 · form4-10172024_091039.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,490 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.1521 to $27.9631. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 04, 2024 Filed Oct 8, 2024 22:54 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 2,825 | $27.51 | $77,703.60 |
DisclosureSEC source: 0001415889-24-024899 · form4-10082024_101045.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,760 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 22:43 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 518 | $27.54 | $14,264.32 |
DisclosureSEC source: 0001415889-24-024668 · form4-10032024_101042.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,585 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.52 to $27.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 20:17 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $22.41 | $28,458.16 |
DisclosureSEC source: 0001415889-24-023610 · form4-09182024_080929.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,103 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.11 to $22.715. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 23:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 620 | $23.70 | $14,695.67 |
DisclosureSEC source: 0001415889-24-021644 · form4-08192024_110843.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,373 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $23.44 to $23.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 23:49 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 650 | $22.82 | $14,830.53 |
DisclosureSEC source: 0001415889-24-021644 · form4-08192024_110843.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,993 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.36 to $23.3588. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 23:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 649 | $27.50 | $17,847.50 |
DisclosureSEC source: 0001415889-24-020685 · form4-08022024_110819.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 27,918 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. F4 · ownership.nature: The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 23:22 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,702 | $27.51 | $46,815.04 |
DisclosureSEC source: 0001415889-24-020685 · form4-08022024_110819.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,643 F1 · kind: The sales reported on this Form 4 were effected pursuant to Rule 10b5-1 trading plans adopted by the Reporting Person and by RAHD Capital LLC on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $27.50 to $27.655. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 23:25 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $24.80 | $31,496.76 |
DisclosureSEC source: 0001415889-24-019731 · form4-07172024_110722.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,345 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.22 to $25.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 23:20 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $21.48 | $27,277.95 |
DisclosureSEC source: 0001415889-24-017715 · form4-06202024_110634.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,615 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.22 to $22.0783. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:21 UTC | Oric Pharmaceuticals, Inc. ORIC · Entity 4765 | GrantStock Option (right to buy) · Derivative | 25,600 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001415889-24-016903 · form4-06142024_080630.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,600 Underlying: Common Stock · 25,600 shares Expires 2034-06-11 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-24-016214 · form4-06102024_080647.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024. Read SEC document |
| May 16, 2024 Filed May 20, 2024 23:46 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $23.74 | $30,149.67 |
DisclosureSEC source: 0001415889-24-013833 · form4-05202024_110525.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,885 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $23.525 to $24.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 15, 2024 Filed Apr 15, 2024 23:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 80 | $20.68 | $1,654.18 |
DisclosureSEC source: 0001415889-24-010825 · form4-04152024_110425.xml · nonDerivative · entry 3 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,155 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.64 to $20.76. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 15, 2024 Filed Apr 15, 2024 23:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,190 | $19.94 | $23,728.96 |
DisclosureSEC source: 0001415889-24-010825 · form4-04152024_110425.xml · nonDerivative · entry 2 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,235 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.61 to $20.5558. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 23:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 649 | $25.00 | $16,225.00 |
DisclosureSEC source: 0001415889-24-010825 · form4-04152024_110425.xml · nonDerivative · entry 4 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 28,567 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F5 · ownership.nature: The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member. Read SEC document |
| April 11, 2024 Filed Apr 15, 2024 23:03 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 5,045 | $25.03 | $126,279.38 |
DisclosureSEC source: 0001415889-24-010825 · form4-04152024_110425.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 138.425 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.00 to $25.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 22:41 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $14.50 | $18,418.68 |
DisclosureSEC source: 0001415889-24-008883 · form4-03212024_100359.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,470 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $14.50 to $14.725. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 21:59 UTC | RayzeBio, Inc. RYZB · Entity 93779 | Disposition to issuerCommon Stock | 367,446 | $62.50 | $22,965,375.00 |
DisclosureSEC source: 0001415889-24-005525 · form4-02272024_090252.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount. Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 00:41 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | SaleCommon Stock | 1,270 | $17.42 | $22,117.43 |
DisclosureSEC source: 0001415889-24-004495 · form4-02212024_120234.xml · nonDerivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,740 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.25 to $17.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 01:52 UTC | Enliven Therapeutics, Inc. ELVN · Entity 4024 | GrantStock Option (right to buy) · Derivative | 21,043 | $0.00 Strike: $14.85 | $0.00 |
DisclosureSEC source: 0001415889-24-004018 · form4-02162024_010226.xml · derivative · entry 1 Heyman Richard A. · CIK 0001584759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,043 Underlying: Common Stock · 21,043 shares Expires 2034-02-12 F1 · derivative.exercise_date: 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.